MYOMO has consistently reported quarterly losses while surpassing revenue expectations in recent earnings announcements. The company secured a significant loan facility in late 2025 and maintains a strong liquidity position as of year-end 2025.

• MYOMO reported a net loss for Q4 2025 but revenue exceeded expectations, continuing a pattern of quarterly losses with revenue outperformance [N1].
• The company announced Q3 2025 results with a loss but revenue again topped estimates [N3].
• Q2 2025 financial results showed a loss with revenue surpassing expectations [N5].
• Q1 2025 results also reflected a loss but revenue was above estimates [N7].
• MYOMO entered into a Loan and Security Agreement in November 2025 for up to $17.5 million in term loans with Avenue Capital Management, including warrants and financial covenants [S11,S13].

MYOMO demonstrates operational continuity with consistent quarterly revenue exceeding expectations despite net losses, indicating market demand for its products. The company's strong liquidity position, with a current ratio of 3.3 and cash ratio of 2.2, provides financial flexibility. The experienced board and management team bring expertise in medical devices and commercialization, which may support strategic growth initiatives. The loan agreement with Avenue Capital Management provides committed capital and equity participation through warrants, potentially aligning lender and company interests.

MYOMO has reported net losses for the fiscal year 2025 and prior quarters, reflecting ongoing challenges in achieving profitability. The company's reliance on debt financing with financial covenants introduces risks related to compliance and potential liquidity constraints. The medical device industry is highly competitive and regulated, which may impact MYOMO's ability to scale or maintain market share. The absence of recent updated revenue figures beyond 2022 limits visibility into current top-line performance. Continued losses and cash burn may pressure financial resources and require additional capital raising.

MYOMO's moat is derived from its specialized medical device technology aimed at improving mobility, supported by a management team and board with deep industry experience. The company's ability to secure financing through committed loans with covenants and warrants suggests investor confidence in its business model. However, the company operates in a competitive and regulated medical device market, requiring continuous innovation and regulatory compliance to maintain its position. The presence of experienced directors and executives with backgrounds in medical technology and commercialization supports strategic oversight and potential competitive advantage.

• Financial Performance Risk: MYOMO has reported net losses and negative earnings per share, indicating challenges in achieving profitability and potential ongoing cash burn.
• Liquidity and Financing Risk: The company relies on committed term loans with financial covenants that require maintaining minimum cash balances and revenue targets, posing risks if these covenants are breached.
• Market and Competitive Risk: Operating in the medical device sector, MYOMO faces competition and regulatory hurdles that may affect product commercialization and market acceptance.
• Operational Execution Risk: Successful execution of business strategies depends on management and board effectiveness, as well as the ability to innovate and comply with regulatory requirements.

• MYOMO, INC. is a Delaware corporation with common stock trading on NYSE American under the ticker MYO [S1].
• As of December 31, 2025, MYOMO had 38,511,715 shares of common stock outstanding [S1].
• The company reported a net loss of $15,573,884 for the fiscal year ended December 31, 2025 [S1].
• Basic and diluted earnings per share for 2025 were both -$0.37 [S1].
• MYOMO's cash and cash equivalents as of December 31, 2025 were $14,132,027, with short-term investments of $4,261,782, totaling $18,393,809 in liquid assets [S1].
• Current assets were $27,557,085 and current liabilities were $8,345,329 as of December 31, 2025, resulting in a current ratio of 3.3 and a cash ratio of 2.2 [S1].
• The company reported revenue of $1 billion for the fiscal year ended August 16, 2022, the latest revenue figure available in filings [S1].
• MYOMO has a board of directors composed of six members with staggered three-year terms, including independent directors with extensive experience in medical devices and healthcare [S1].
• The executive team includes President, CEO and Chairman Paul R. Gudonis, CFO David A. Henry, Chief Commercial Officer Micah J. Mitchell, and Chief Medical Officer Harry Kovelman, M.D. [S1].
• MYOMO entered into a Loan and Security Agreement in November 2025 providing committed term loans up to $17.5 million with Avenue Capital Management II, L.P., bearing interest at prime plus 4.75%, maturing June 1, 2029 [S11,S13].
• The loan agreement includes financial covenants requiring maintenance of $2.5 million in unrestricted cash, minimum revenue achievement, and limits on cash burn [S10].
• The company issued warrants to the lender to purchase common stock with an exercise price subject to adjustments, expiring in 2030 [S12].
• MYOMO regularly reports quarterly financial results, consistently reporting losses but topping revenue expectations in recent quarters [N1,N3,N5,N7].
• Recent news coverage includes MYOMO's Q4 2025 loss report with revenue exceeding estimates, and similar quarterly reports for Q3, Q2, and Q1 2025 [N1,N3,N5,N7].